
SION Stock Forecast & Price Target
SION Analyst Ratings
Bulls say
Sionna Therapeutics is a promising biopharmaceutical company focused on developing innovative treatments for cystic fibrosis, with potential revenue of $4.3 billion from their lead drug SION-719. While upcoming clinical data and competition from Vertex Pharmaceuticals may impact their stock, Sionna's positive outlook is supported by their pipeline programs and ongoing Phase 3 study for SION-719. However, their ultimate success will be determined by the results of their clinical trials and their ability to compete in the large CF market.
Bears say
Sionna Therapeutics is a promising company in the cystic fibrosis market, with a potential launch of their CFTR modulator targeting NBD1 in 2030. However, the risks and challenges associated with developing and commercializing rare disease treatments should not be overlooked, as well as potential competition in the market. Furthermore, any delays in the pipeline could also impact Sionna's success.
This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SION Analyst Forecast & Price Prediction
Start investing in SION
Order type
Buy in
Order amount
Est. shares
0 shares